MDT Q3 2026 Earnings Analysis
Listen On
Available In
Key Highlights
- Revenue and earnings analysis for Q3 2026
- Key financial metrics and performance indicators
- Management guidance and outlook commentary
- Market position and competitive analysis
- AI-generated insights and analysis
Transcript
// Full episode scriptBeta Finch Podcast Script - Medtronic Q3 2026 Earnings
Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex quarterly reports into clear insights. I'm Alex.
And I'm Jordan. Today we're diving into Medtronic's Q3 2026 results, and wow - this was quite the quarter for the medical device giant.
Before we jump in, I need to share our mandatory disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Right, thanks Alex. So Medtronic - ticker MDT - just reported some pretty impressive numbers. Let's start with the headline figures. Revenue hit $9 billion, growing 8.7% reported and 6% organically. That's actually a 50 basis point acceleration from the prior quarter.
And they beat their own guidance by 50 basis points too. The real star here was their cardiovascular portfolio, which grew 11% year-over-year - that's the strongest growth they've seen in cardiovascular in the last ten years, excluding COVID comps.
The standout within cardio was their Cardiac Ablation Solutions, or CAS business, which includes their pulse field ablation technology. This grew 80% year-over-year, with PFA accounting for 80% of that revenue. CEO Geoffrey Martha seems really excited about this - they're calling it one of their "generational growth drivers."
Speaking of growth drivers, Medtronic is really pushing four major ones: their PFA technology, the Simplicity Spyral system for hypertension, Altaviva for urinary incontinence, and their Hugo surgical robot. Jordan, what caught your attention in the management commentary?
What's fascinating is how they're building entirely new markets. Take their Simplicity system for hypertension - they launched a direct-to-consumer campaign called "Go Beyond" and saw website visits jump from 50,000 in Q2 to 2.5 million in Q3. That's a 50x increase! They opened over 200 new accounts this quarter and now have about 100 million covered lives, which is roughly one-third of the US population.
That consumer demand story is really compelling. And it sounds like they're seeing great patient outcomes, which is driving physician excitement. But let's talk numbers - what about profitability?
Adjusted EPS came in at $1.36, beating the midpoint of guidance by 3 cents. However, gross margins are taking a hit from business mix - specifically from CAS and their Diabetes business. CFO Thierry Pieton explained that CAS currently has an unfavorable mix of lower-margin capital equipment to higher-margin catheters, since they're still in early launch phase.
But that should improve over time as the installed base grows and catheter sales increase relative to the initial capital equipment, right?
Exactly. Pieton said they expect to see that mix inflection in the second half of next year, with CAS actually driving gross margin improvement as early as fiscal 2027. There's also the Diabetes business separation they're planning - since Diabetes has lower margins than the rest of the business, spinning it off should provide a natural margin lift.
Let's talk about that guidance for fiscal 2027. They're maintaining their expectation for high-single-digit EPS growth, but there are some moving pieces.
Right, there are several puts and takes. They'll have a full year of tariff impact - about $300 million versus $185 million in 2026. There's an extra selling week that will help growth. And the Diabetes separation will create some temporary dilution of 1-2 cents per month between the IPO and the full split, since they lose 20% of Diabetes profits but don't get the share buyback benefit until the full separation.
The Q&A session had some interesting moments. One analyst asked about their capital allocation strategy, particularly around the CathWorks acquisition and Enteris investment. What's Medtronic's M&A philosophy?
Martha was clear they're focused on "tuck-in" deals - potentially several billion dollars each, but adjacent to existing businesses rather than transformational mega-deals. They want multiple shots on goal in high-growth markets, similar to how they approached pulse field ablation with both organic development and the Afera acquisition.
There was also discussion about their Hugo robotic surgery system. They just got FDA clearance for urologic procedures and completed their first US cases at Cleveland Clinic. But interestingly, Martha didn't include Hugo in the group of products that will kick in as soon as Q4, like Simplicity and Altaviva.
That suggests Hugo might take a bit longer to move the needle on their large $6 billion Surgical business. Though the leading indicators sound positive - installations are stepping up globally, and they're seeing strong utilization rates.
One product that seems underappreciated is their Stealth Axis system for spine surgery. Martha was pretty emphatic that this isn't just an extension of their existing Mazor robot - it's a completely new platform.
What makes it interesting is how it fits into existing surgical workflows. Currently, 70% of spine procedures in the US use navigation technology that Medtronic invented and leads. Traditional robotics don't integrate well with that workflow, but Stealth Axis creates one seamless system from imaging to AI-based planning to the actual procedure. It essentially lowers barriers for surgeons to adopt robotics.
Looking at the broader picture, what does this quarter tell us about Medtronic's trajectory?
They seem to be hitting an inflection point where multiple growth drivers are starting to contribute simultaneously. You have CAS already delivering strong growth, renal denervation and Altaviva beginning to ramp, Hugo launching in the US, and Stealth Axis just getting FDA clearance. Plus their traditional businesses like CRM and Peripheral Vascular showed acceleration this quarter.
The company feels more confident and aggressive than we've seen in a while. They're increasing R&D spending, ramping up direct-to-consumer marketing, hiring aggressively - particularly those cardiac mapping specialists for their PFA business - and accelerating M&A activity.
Martha used the phrase "shifting our stance, moving into more of an offensive footing" - that really captures the tone. They see momentum building and are investing ahead of it.
Any concerns investors should watch?
The main near-term headwinds are tariffs and the temporary dilution from the Diabetes separation. Longer-term, execution will be key - they're essentially building multiple new markets simultaneously, which requires significant investment and flawless execution.
Before we wrap up, everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
For Medtronic, this quarter suggests they're successfully transitioning from a traditional medical device company focused on incremental innovation to one with multiple breakthrough technologies launching simultaneously. If execution continues, fiscal 2027 could be a strong year. I'm Alex.
And I'm Jordan. Thanks for listening to Beta Finch, and we'll see you next time for another AI-powered earnings breakdown.